

## DAFTAR PUSTAKA

- Ahmad, S. and Mokaddas, E. 2009, Recent Advances in the Diagnosis and Treatment of Multidrug-resistant Tuberculosis, *Respir Med*, **103**:1777-1790.
- Alisjahbana, B., van Crevel, R., Sahiratmadja E., den Heijer, M., Maya, A., Istriana, E., *et al.* 2006, Diabetes mellitus is strongly associated with tuberculosis in Indonesia, *Int J Tuberc Lung Dis*, **10(6)**:696–700
- Arbex, M.A., Varella, M.C, Siqueira, H.R. and Mello, F.A. 2010, Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs, *J Bras Pneumol*, **36**:626–640.
- Aslam, M. 2003, *Farmasi Klinik (Clinical Pharmacy), Menuju Pengobatan Rasional dan Penghargaan Pasien*, Elek Media Komputindo, Jakarta, Indonesia
- Bam, T.S., Aditama, T.Y., Chiang, C.Y., Rubaeah, R. and Suhaemi, A. 2015, Smoking cessation and smokefree environments for tuberculosis patients in Indonesia-a cohort study, *BMC Public Health*, **15**:604, 1-8
- Bernabe-Ortiz, A., Carcamo, C.P., Sanchez, J.F. and Rios, J. 2011, Weight Variation over Time and Its Association with Tuberculosis Treatment Outcome: A Longitudinal Analysis, *PLoS ONE*, **6(4)**: e18474. doi:10.1371/journal.pone.0018474
- Bhardawaj, A., Kumar, R., Dabas, V., and Alam, N. 2012, Assessment and Enhancing Adherence to Treatment Regimen in Tuberculosis Out Patient, *Int J Pharm Pharm Sci*, **4(3)**:517-522.
- Blumberg, H.M., Burman, W.J., Chaisson, R.E., Daley, C.L., Etkind, S.C., Freidman, A.N., *et al.* 2003, American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease Society of America: Treatment of Tuberculosis, *Am J Respir Crit Care Med*, **167**:604-662
- Bosch-Capblanch, X., Abba, K., Prictor, and M., Garner, P. 2007. Contracts between patients and healthcare practitioners for improving patients' adherence to treatment, prevention and health promotion activities. *Cochrane Database of Systematic Reviews*, Issue 2. Art. No.: CD004808. DOI: 10.1002/14651858.CD004808.pub3.
- Case Management Society of America. 2006, Case Management Adherence Guidelines version 2.0; viewed 1 May 2014 <<http://www.cmsa.org.prtals/o/pdf/CMAG2.pdf>>.



- Castro, A.T., Mendes, M., Freitas, S. and Roxo, P.C. 2015, Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years, *Rev Port Pneumol*, **21(3)**:144---150
- Centers for Disease Control and Prevention. 2008, *Self-Study Modules on Tuberculosis: Module 1-9*, Division of Tuberculosis Elimination CDC, Atlanta, Georgia.
- Chahine, E.B., Sourial, M. and Scales, J. 2012, Role of the Pharmacist in the Management of Adults With Pulmonary Tuberculosis, *US Pharm*, **37(7)**:HS2-HS6.
- Clark, P.M., Karagoz, T., Apikoglu-Rabus, S., and Izzettin, F.V. 2007, Effect of pharmacist-led patient education on adherence to tuberculosis treatment, *Am J Health-Syst Pharm*, **64**:497-506
- Coleman, L.T, Adams, W.C. and Gong, W.C. 1983, Pharmacist as a primary-care provider in a tuberculosis clinic, *Am J Hosp Pharm*, **40(2)**:278-81.
- Craig, P., Dieppe, P., Macintyre, S., Michie, S., Nazareth, I., Petti crew, M., *et al.* 2008, Developing and evaluating complex interventions: the new Medical Research Council guidance, *BMJ*, **337**:a1655.
- Dahlan MS. 2010, *Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan*, Penerbit Salemba Medika, Jakarta, Indonesia
- Dale, D.C. 2003, *Infectious Disease : The Clinician's Guide to Diagnosis, Treatment, and Prevention*, WebMD Inc., New York, USA
- Dayton, C.S. 1978. Pharmacist involvement in a tuberculosis outpatient clinic, *AJHP*, **35(6)**: 708-710
- den Boon, S., van Lill, S.W.P., Borgdorff, M.W., Verver, S., Bateman, E.D., Lombard, C.J., *et al.* 2005, Association between smoking and tuberculosis infection: a population survey in a high tuberculosis incidence area, *Thorax*, **60**:555–557
- Departemen Kesehatan Republik Indonesia. 2005, *Pharmaceutical Care Untuk Penyakit Tuberkulosis*, Jakarta, Departemen Kesehatan Republik Indonesia.
- Departemen Kesehatan Republik Indonesia. 2008, *Pedoman pelayanan kefarmasian di rumah (home pharmacy care)*, Jakarta, Departemen Kesehatan Republik Indonesia.
- Departemen Kesehatan Republik Indonesia. 2009, *Buku Saku Kader Program Penanggulangan TB*, Jakarta, Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan Departemen Kesehatan RI



Departemen Kesehatan Republik Indonesia. 2011, *Pedoman Nasional Pengendalian Tuberkulosis*, Jakarta, Departemen Kesehatan Republik Indonesia.

Departemen Kesehatan Republik Indonesia. 2012, Keberhasilan upaya pengendalian TB ditentukan oleh dukungan semua pihak dan seluruh lapisan masyarakat. [diunduh 16 Maret 2015]. Tersedia dari: <http://www.depkes.go.id/article/view/1873>

Edwards, I.R. and Aronson, J.K. 2000, Adverse Drug Reactions: Definitions, Diagnosis, and Management, *Lancet*, **356**:1255-1259.

Esmael, A., Ali, I., Agonafir, M., Desale, A., Yaregal, Z. and Desta, K. 2013, Assessment of Patients' Knowledge, Attitude, and Practice Regarding Pulmonary Tuberculosis in Eastern Amhara Regional State, Ethiopia: Cross-Sectional Study; *Am. J. Trop. Med. Hyg*, **88(4)**:785-788

Fadila, R.N. dan Pandu, R. 2014. Pengaruh Rejimen terhadap Ketidakpatuhan Berobat Tuberkulosis, *Kesmas: Jurnal Kesehatan Masyarakat Nasional*, **9(2)**:107-112

Francis, M.T., and Chandrasekaran, K. 2012, Effectiveness of Knowledge Based Approach for the Provement of Patient Adherence and Reducing the Severity of Adverse Drug Reaction in Anti Tubercular Therapy, *IJPTP*, **3(3)**:313-317

GERDUNAS-TB, 2001, *Modul Pelatihan Penanggulangan Tuberkulosis Nasional*, Gerakan Terpadu Nasional Penanggulangan Tuberkulosis, Jakarta

Gnanasan, S., Ting, K.N., Wong, K.T., Mohd Ali, S., Muttalif, A.R. and Anderson, C. 2011, Convergence of tuberculosis and diabetes mellitus: time to individualise pharmaceutical care, *IJCP*, **33**:44-52.

Government of India and Indian Pharmaceutical Association. 2013, *Revised National Tuberculosis Control Programme, Training Module for Community Pharmacist*, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi, India

Grahame-Smith, D.G., and Aronson, J.K. 2002, *Oxford Textbook of Clinical Pharmacology and Drug Therapy*, 3<sup>rd</sup> Ed., Oxford University Press, UK.

Gulbay, B.E, Gurkan, O.U., Yıldız, O.A., Onen, Z.P., Erkeköl, F.O., Baccioğlu, A, et al. 2006, Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis, *Respir Med*, **100**:1834-1842.

Harries A., 2004, What are the most common adverse drug events to first-line tuberculosis drugs, and what is the procedure for reintroduction of drugs? in WHO, 2004, *Toman's Tuberculosis Case detection, treatment, and monitoring – questions and answers*, WHO, Geneva, pp 152-158



- Hoa, N.P., Diwan, V.K., and Thorson, A.E.K. 2005, Diagnosis and treatment of pulmonary tuberculosis at basic health care facilities in rural Vietnam: a survey of knowledge and reported practices among health staff, *Health Policy*, **72**: 1–8
- Huang ,Y.S. 2014, Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury, *J Chin Med Assoc*, **77**:169–173
- Kanjee, Z., Catterick, K., Moll, A.P., Amico, K.R., and Friedland, G.H. 2011, Tuberculosis infection control in rural South Africa: survey of knowledge, attitude and practice in hospital staff, *J Hosp Infect*, **79**:333-338.
- Kanyok, T. P. 1997, Combating tuberculosis, *Am J Health Syst Pharm*, **54**:375
- Kayigamba, F.R., Bakker, M.I., Mugisha, V., De Naeyer, L., Gasana, M., Cobelens, F., *et al.* 2013, Adherence to Tuberculosis Treatment, Sputum Smear Conversion and Mortality: A Retrospective Cohort Study in 48 Rwandan Clinics, *PLoS ONE*, **8(9)**: e73501. doi:10.1371/journal.pone.0073501
- Kennie, N.R., Schuster, B.G., and Einarson, T.R. 1998, Critical analysis of the pharmaceutical care research literature. *Ann Pharmacother*, **32**:17-26.
- Liam, C.K., Lim, K.H., Wong, C.M.M., Tang, B.G. 1999, Attitudes and knowledge of newly diagnosed tuberculosis patients regarding the disease, and factors affecting treatment compliance, *Int J Tuberc Lung Dis*, **3(4)**:300–309
- Liu, Q., Abba, K., Alejandria, M.M., Balanag, V.M., Berba, R.P., and Lansang, M.A.D. 2008. 2008, Reminder systems and late patient tracers in the diagnosis and management of tuberculosis, *Cochrane Database of Systematic Reviews*, Issue 4. Art. No.: CD006594. DOI: 10.1002/14651858.CD006594.pub2.
- Lutge, E.E., Wiysonge, C.S., Knight, S.E., and Volmink, J. 2012. Material incentives and enablers in the management of tuberculosis, *Cochrane Database of Systematic Reviews*, Issue 1. Art. No.: CD007952. DOI: 10.1002/14651858.CD007952.pub2.
- M’Imunya, J.M., Kredo, T., and Volmink, J. 2012, Patient education and counselling for promoting adherence to treatment for tuberculosis (Review), *Cochrane Database of Systematic Reviews*, Issue 5. Art. No.: CD006591. DOI: 10.1002/14651858.CD006591.pub2.
- Marra, F., Marra, C.A., Bruchet, N., Richardson, K., Moadebi, S., Elwood, R.K., *et al.* 2007, Adverse drug reactions associated with first-line anti-tuberculosis drug regimens, *Int J Tuberc Lung Dis*, **11**: 868–875.



- McDonald, H.P., Amit, X.G., and Brian, H. 2002, Interventions to Enhance Patient Adherence to Medication Prescriptions: Scientific Review, *JAMA*, **288(22)**: 2868-2879.
- McDonnell, M., Turner, J., and Weaver, M.T. 2001, Antecedents of adherence to antituberculosis therapy, *Public Health Nurs*, **18(6)**:392-400
- Medecins Sans Frontieres. 2013, *Checklists for Patient education/counselling sessions for those with active TB disease, Including drug-resistant TB*, MSF OCB, Georgia.
- Minnery, M., Contreras, C., Perez, R., Solorzano, N., Tintaya, K., Jimenez, J. *et al.* 2013, A Cross Sectional Study of Knowledge and Attitudes Towards Tuberculosis amongst Front-Line Tuberculosis Personnel in High Burden Areas of Lima, Peru. *PloS ONE* **8(9)**:e75698. Doi:10.1371/journal.pone.0075698.
- Mitrzyk, B.M. 2008, Treatment of extensively drug-resistant tuberculosis and role of the pharmacist, *Pharmacotherapy*, **28(10)**: 1243-1254
- Mkele, G. 2010, The role of the pharmacist in TB management, *SA Pharmaceutical Journal*, 18-21.
- Morisky, D.E, Mallotte, C.K., Ebin, V., Davidson, P., Cabrera, D., Trout, P.T., *et al.* 2001, Behavioral Intervention for the Control of Tuberculosis Among Adolescents, *Public Health Report*, **116**:568-574
- MRC. 2000, *A framework for development and evaluation of RCTs for complex interventions to improve health*. London: Medical Research Council.
- Nakatani, H. And Buchmann M. 2011, The role of the pharmacist in Tuberculosis care and control, *Signing ceremony\_WHO/FIP Joint Statement*:1-4
- Navio, J.L.P., Yuste, M.R. and Pasicatan, M.A. 2002, Socio-economic determinants of knowledge and attitudes about tuberculosis among the general population of Metro Manila, Philippines, *Int J Tuberc Lung Dis*, **6(4)**:301–306
- Ng, N., Padmawati, R.S., Prabandari, Y.S., and Nichter, M. 2008, Smoking behavior among former tuberculosis patients in Indonesia: intervention is needed, *Int J Tuberc Lung Dis*, **12(5)**:567–572
- Osterberg, L. and Blaschke, T. 2005, Adherence to medication., *NEJM*, **353**:487-497.
- Pajares, F. 1996, Self-Efficacy Beliefs in Academic Setting, *RER*, **66(4)**: 543-578



- Peloquin, C.A. 2008, 'Tuberculosis', in Dipiro, J.T., Talbert, R.L., Yee G.C., Matzke G.R., Wells A.G., and Posey L.M., *Pharmacotherapy : A Pathophysiologic Approach*, 7<sup>th</sup>Ed, Appleton & Lange, Stamford
- Pesut, D.P., Bursuc , B.N., Bulajic, M.V., Solovic, I., Kruczak, K., Duarte, R. *et al.* 2014, Illness perception in tuberculosis by implementation of the Brief Illness Perception Questionnaire – a TBNET study, *SpringerPlus*, **3**:664
- Phillips, D.E., Hill, L., and Weller, P. 2003, Tobacco smoke and the upper airway, *Clin Otolaryngol*, **28**:492–6.
- Putera, I., Pakasi, A.T., and Karyadi, E. 2015, Knowledge and perception of tuberculosis and the risk to become treatment default among newly diagnosed pulmonary tuberculosis patients treated in primary health care, East Nusa Tenggara: a retrospective study, *BMC Res Notes*, **8**:238
- Rachmawati, F. D. 2011, Gambaran Kepatuhan Berobat dan Kualitas Hidup Penderita Tuberkulosis Rawat Jalan RSUP Dr. Sardjito Yogyakarta Periode Maret-Mei 2011, *Skripsi*, Fakultas Farmasi, Universitas Gadjah Mada.
- Roy, A., Abubakar, I., Chapman, A., Andrews, N., Pattinson, M., Lipman, M., et al. 2011. A Controlled Trial of the Knowledge Impact of Tuberculosis Information Leaflets among Staff Supporting Substance Misusers: Pilot Study, *PLoS ONE* **6(6)**:e20875. Doi:10.1371/journal.pone.0020875.
- Sacket, D.L., Haynes, R.B., Guyatt, G.H., dan Tugwell P. 1991, *Clinical Epidemiologi : A Basic Science for Clinical Medicine*, Little Brown and Company, Boston, Toronto dan London, pp 27-28.
- Santoso, S., 2010, *Metode Penelitian Kuantitatif Plus Aplikasi Program SPSS*, Pusat Penelitian Fakultas Ekonomi Universitas Muhammadiyah Ponorogo, Ponorogo
- Schaberg, T., Rebhan, K. and Lode, H. 1996, Risk factors for side-effects of isoniazid, Rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis, *Eur Respir J*, **9**: 2026–2030.
- Schindel, T.J., Kehrer, J.P., Yuksel, N., and Hughes, C.A. 2012, University-based continuing education for pharmacists, *Am J Pharm Educ*, **76(2)**:1-7.
- Shah, N.S., Pratt, R., Amstrong, L., Robinson, V., Castro, K.G., and Cegielski, J.P. 2008, Extensively Drug-Resistant Tuberculosis in The United States 1993-2007. *JAMA*, **300(18)**:2153-2160.
- Singh, A., Prasad, R., Balasubramanian, V., Gupta, N., and Gupta, P. 2015, Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis, *CEGH*, **3**:S80-S90



- Sopori, M. 2002, Effects of cigarette smoke on the immune system, *Nat Rev Immunol*, **2**:372–7.
- Sotgiu, G., and Migliori, G.B. 2014. Facing multi-drug resistant tuberculosis, *Pulm Pharmacol Ther* , **32**:144-148
- Swart A and Harris V, 2005, Drug Interactions with Tuberculosis Therapy, *CME*, 23(2): 56-60.
- Tang, Y. W., Stratton, C. W., Kilic, A., and Drake, W., 2006, Advances in the Diagnosis of Mycobacterium tuberculosis and Detection of Drug Resistance, *Advanced Techniques in Diagnostic Microbiology*.
- Taylor, H.G, 1992, The tuberculosis epidemic and the pharmacist's role, *American Pharmacy*, **32(7)**: 41-44
- Taylor, K. and Harding, G. 2001, *Pharmacy Practice*, Taylor and Francis, London and New York, pp 166-172
- The New Jersey Medical School Global Tuberculosis. 2005, *What you Need to Know About Tuberculosis Flipbook*, NJMS Global Tuberculosis Institute, US.
- Thiam, S., LeFevre, A.M., Hane, F., Ndiaye, A., Ba, F., Fielding, K. L., *et al.* 2007, Effectiveness of a Strategy to Improve Adherence to Tuberculosis Treatment in a Resource-Poor Setting: A Cluster Randomized Controlled Trial, *JAMA*, **297(4)**:380-386.
- Thompson, N.P, Caplin, M.E, Hamilton, M.I, Gillespie, S.H., Clarke S.W, Burroughs A.K., *et al.* 1995, Anti-tuberculosis medication and the liver: dangers and recommendations in management, *Eur Respir J*, **8**: 1384–1388.
- Tissera, W.A.A. 2003, *Non-Compliance with Anti-Tuberculosis Treatment at Colombo Chest Clinic*, *NTI Buletin*, 39/1&2, 5-9, Medical Officer, Central Chest Clinic, Srilanka
- Tulip, S. and Campbell, D. 2001, Evaluating pharmaceutical care in hospitals, *Hospital Pharmacists*, **8**:275-279.
- United States Agency for International Development. 2005, *A Trainers Guide for A Workshop On Tuberculosis For Pharmacy Staff in Cambodia, 2005-2011*, USAID, Cambodia.
- United States Agency for International Development. 2012, *Multidrug-resistant tuberculosis: What every patient should know Flipchart Generic*, TB CARE II, USAID, US.



Vlasses, P.H. 2006, Pharmacy continuing education: 40 years ago to now. *Ann Pharmacother*, **40(10)**:1854-1856.

Volmink, J. and Garner, P. 2009, Directly observed therapy for treating tuberculosis, *The Cochrane Collaboration*, **4**:1-32

Westerlund, E.E., Tovar, M.A., Lo'nnnermark, E., Montoya, R. And Evans, C.A. 2015, Tuberculosis-related knowledge is associated with patient outcomes in shantytown residents; results from a cohort study, Peru, *J Infect*, **71**: 347-357

Wing, W.Y. and Chi, C.L. 2006, Antituberculosis drugs and hepatotoxicity, *Respirology*, **11**: 699–707.

Wong, I.C.K. 2004, Randomised controlled trials (RCTs) to evaluate complex healthcare interventions - a case study, *Pharm World Sci*, **26**:247-252.

World Health Organization. 2002, *The Importance of Pharmacovigilance : Safety monitoring of medicinal products*, Geneva, WHO.

World Health Organization (WHO). Adherence to Long-Term Therapies: Evidence for action, *Geneva*, WHO, 2003

World Health Organization. 2003, *Report on Medication Adherence*, Geneva, WHO.

World Health Organization. 2006, *The safety of medicines in public health programmes: pharmacovigilance an essential tool*, Geneva, WHO.

World Health Organization. 2010, *Treatment of Tuberculosis Guidelines*, 4<sup>th</sup> ed, Geneva, WHO.

World Health Organization. 2012, *A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis: enhancing the safety of the TB patient*, Geneva, WHO.

World Health Organization. 2015, *Global Tuberculosis Report 2015*, Geneva, WHO.

Wu, P.S., Chou, P., Chang N.T., Sun, W.J., and Kuo, H.S. 2009, Assessment of Changes in Knowledge and Stigmatization Following Tuberculosis Training Workshops in Taiwan, *J Formos Med Assoc*, **108(5)**:377-385.

Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I. and Menzies, D. 2003, Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis, *Am J Respir Crit Care Med*, **167**: 1472–1477.



UNIVERSITAS  
GADJAH MADA

**Aplikasi Model Training-Education-Monitoring-Adherence-Networking (TEMAN) Apoteker dalam Meningkatkan Kualitas Pelayanan Pasien Tuberkulosis di Yogyakarta**  
NANANG MUNIF YASIN, Prof. Dr. Djoko Wahyono, SU., Apt.; dr. Bambang Sigit Riyanto, Sp.PD., KP.; Ika Puspita S  
Universitas Gadjah Mada, 2016 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Yew, W.W. 2002, Clinically Significant Interactions with Drugs Used in the Treatment of Tuberculosis, *Drug Safety*, **25(2)**:111-133

Zaleskis, R. 2005. 'Postgraduate Course ER Copenhagen 2005: The side-effects of TB therapy', *Breathe*, **2 (1)**: 69-73.